Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: Crsp - The Untold Story

3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotech M&A is surging ahead of a $300B patent cliff. Here are 3 gene-editing stocks investors are watching as potential acquisition targets

MarketBeat

This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.

Cathie Wood recently added to her position in CRISPR Therapeutics stock.

Barchart

CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows

Get context for CRISPR Therapeutics’ Q4 results: CASGEVY launch economics, cash runway, pipeline upside, and the technical level investors should watch.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Over 4 million working households now struggling to afford a decent life, research finds

More than four million working households across the UK are not earning enough to afford a “decent life”, according to new research.

The Independent UK

Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics

On Friday, Cathie Wood-led Ark Invest made significant trades in the market, with the most prominent ones being in Veracyte Inc. (NASDAQ:VCYT), Iridium Communications Inc. (NASDAQ:IRDM), CRISPR Therapeutics AG (NASDAQ:CRSP), Kratos Defense Security Solutions Inc. (NASDAQ:KTOS), Absci Corp. (NASDAQ:ABSI), Veeva Systems Inc. (NYSE:VEEV), Adaptive Biotechnologies Corp. (NASDAQ:ADPT) and Guardant Health…

Benzinga

CRSPR Stock Could Be Ready to Deliver on Its Massive Promise

CRSPR Therapeutics has ambitious goals for its gene editing technology and may be getting ready to generate the revenue needed to deliver for shareholders

MarketBeat

The Best Large-Cap Stocks to Buy

Large-cap stocks are key additions to any well-rounded portfolio. Let's take a look at how to find the best ones for you.

Kiplinger

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks With Strong Value in August

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

StockNews.com

3 of the Worst Stocks on Wall Street Right Now

The growing concerns about a potential recession, ongoing debt ceiling standoff, and predictions of prolonged high-interest rates might weigh on the US economy and stock market. Hence, it might be best to avoid fundamentally weak stocks CRISPR Therapeutics (CRSP), First Majestic Silver (AG), and McEwen Mining (MUX). Keep reading.

StockNews.com

3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner

CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.

Benzinga

4 Genomics Stocks to Consider Buying After the Crash

The genomics industry is poised to grow significantly in 2022, driven by strong demand amid the increasing need for personalized medicine and the rising population with serious illnesses. Thus, beaten-down genomics stocks Invitae (NVTA), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), and CRISPR Therapeutics (CRSP) could be ideal investments now.

StockNews.com

Analysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive

CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematologic malignancies.

Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

Benzinga

$100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 13.5% on an annualized basis producing an average annual return of 25.08%. Currently, CRISPR Therapeutics has a market capitalization of $4.02 billion.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What 4 Analyst Ratings Have To Say About CRISPR Therapeutics

Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings:

StockNews.com

5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022, supported by strong demand for healthcare and medical products and increasing investments in R&D. Given these factors, Wall…

Benzinga

$1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth This Much

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.85% on an annualized basis producing an average annual return of 28.2%. Currently, CRISPR Therapeutics has a market capitalization of $4.51 billion.

Benzinga

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.09% on an annualized basis producing an average annual return of 26.02%. Currently, CRISPR Therapeutics has a market capitalization of $5.12 billion.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 12.95% on an annualized basis.

Benzinga

Why Jim Cramer Believes Sirius XM Is Inexpensive

On CNBC’s "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: CRSP) is likely to "lose a lot of money.

Benzinga

CRISPR Therapeutics's Return On Capital Employed Insights

Benzinga Pro data, CRISPR Therapeutics (NASDAQ:CRSP) reported Q4 sales of $12.90 million. Earnings fell to a loss of $141.25 million, resulting in a 11.09% decrease from last quarter.

Benzinga

Here's How Much You Would Have Made Owning CRISPR Therapeutics Stock In The Last 5 Years

CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis.

People

Mangeet Kaur BounsMangeet

595 stories

Jim Cramer

515 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Vertex Pharmaceuticals Incorporated

65 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.